Stubbs Alderton & Markiles’ client Edesa Biotech Inc., a clinical-stage biopharmaceutical company, has announced the completion of its business combination transaction with Stellar Biotechnologies, Inc. pursuant to a share exchange agreement entered into on March 7, 2019. The combined company will be called Edesa Biotech, Inc. and commenced trading on the Nasdaq Capital Market on June 10, 2019 under the symbol “EDSA.”
To read the full press release visit here.
Stubbs Alderton & Markiles’ attorneys representing Edesa Biotech in this transaction are Jonathan Friedman and Brent Armitage.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company focused on efficiently developing innovative treatments that address significant unmet medical needs. Edesa’s lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis which has demonstrated statistically significant improvements in multiple clinical studies. Edesa also intends to expand the utility of its sPLA2 inhibitor technology, which forms the basis for EB01, across multiple indications. The company is based in Toronto, Canada, with U.S. offices in Southern California.
For more information about our Corporate & Business Matters practice area please contact Jonathan Fredman at